The present invention provides a compound represented by formula (I) [wherein L represents an oxygen atom or CH.sub.2, E represents a C2-C10 chain hydrocarbon group or the like, R.sup.1 represents a C1-C3 chain hydrocarbon group or the like, R.sup.2 represents a C1-C3 chain hydrocarbon group or the like, and n is 0, 1, 2 or 3.] or its N oxide or agriculturally acceptable salt, which is a compound that have excellent pests controlling effects. ##STR00001##

The present invention provides a compound represented by formula (I) [wherein L represents an oxygen atom or CH.sub.2, E represents a C2-C10 chain hydrocarbon group or the like, R.sup.1 represents a C1-C3 chain hydrocarbon group or the like, R.sup.2 represents a C1-C3 chain hydrocarbon group or the like, and n is 0, 1, 2 or 3.] or its N oxide or agriculturally acceptable salt, which is a compound that have excellent pests controlling effects. ##STR00001##

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention is to provide a polymerizable liquid crystal compound represented by Formula (I);

Q.sup.1-Sp.sup.1A-L.sub.m-1A-Sp.sup.2-Q.sup.2(I)

A represents a divalent nitrogen-containing saturated cyclic group (that may have a substituent) formed by removing two hydrogen atoms from piperidine or piperazine, a phenylene group that may have a substituent, or a trans-1,4-cyclohexylene group that may have a substituent, L represents C(O)O, OC(O), or the like, m represents 3 to 12, Sp.sup.1 and Sp.sup.2 represent an alkylene group having 1 to 20 carbon atoms, any one of Q.sup.1 and Q.sup.2 represents a polymerizable group, Formula (I) has a nitrogen-containing saturated cyclic group and a phenylene group that are directly bonded to each other via C(O)O. By using a polymerizable composition including the polymerizable liquid crystal compound, a film such as a retardation film having low birefringence or a reflection film having high selectivity in a reflection wavelength range can be provided.

The present invention is to provide a polymerizable liquid crystal compound represented by Formula (I);

Q.sup.1-Sp.sup.1A-L.sub.m-1A-Sp.sup.2-Q.sup.2(I)

A represents a divalent nitrogen-containing saturated cyclic group (that may have a substituent) formed by removing two hydrogen atoms from piperidine or piperazine, a phenylene group that may have a substituent, or a trans-1,4-cyclohexylene group that may have a substituent, L represents C(O)O, OC(O), or the like, m represents 3 to 12, Sp.sup.1 and Sp.sup.2 represent an alkylene group having 1 to 20 carbon atoms, any one of Q.sup.1 and Q.sup.2 represents a polymerizable group, Formula (I) has a nitrogen-containing saturated cyclic group and a phenylene group that are directly bonded to each other via C(O)O. By using a polymerizable composition including the polymerizable liquid crystal compound, a film such as a retardation film having low birefringence or a reflection film having high selectivity in a reflection wavelength range can be provided.

Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.